Iqembu le UMkhandlu Ophakeme Wophenyo Lwesayensi (CSIC), nge-Institute of Advanced Chemistry of Catalonia (IQAC), iklame i- i-antibody ye-monoclonal ekwazi ukuqeda ubuthi igciwane eliyingozi kakhulu kwelinye lamagciwane asesibhedlela elikhathaza kakhulu i-World Health Organization: Pseudomonas aeruginosaLeli gciwane, elivame kakhulu ezindaweni zokunakekelwa kwempilo, lithole igama elithi "superbug" ngenxa yekhono lalo lokumelana nama-antibiotic amaningi atholakalayo.
I-antibody entsha, ebizwa ngokuthi mAb122Ayifuni ukubhubhisa i-microorganism ngokuqondile, kodwa vimba i-pyocyaninubuthi obuyisihluthulelo obunciphisa amandla okuzivikela esiguli futhi bukhuthaze ukutheleleka okukhulu. Le ndlela, eyaziwa ngokuthi isu lokulwa negciwane, ibhekwa njengendlela engenzeka yokwenza ukunciphisa ukusetshenziswa kwama-antibiotic ama-classics futhi anciphise ukuvela kokumelana okusha, inkinga ebilokhu iphakamisa izixwayiso ezibhedlela eSpain nakulo lonke elaseYurophu iminyaka eminingi.
Igciwane elibekwe phambili yi-WHO kanye noshintsho kwesu
La Pseudomonas aeruginosa I-WHO ibhale ukuthi ingenye yezifo ezibangela izinkinga ezinkulu emhlabeni jikelele ngenxa yokuthi amandla angavamile okuzivumelanisa nezimo futhi kungaholela ekumelaneni nemithi eminingi. Kuhlotshaniswa nokutheleleka kwamanxeba okuphefumula, okomchamo, noma okuhlinzwa, ikakhulukazi kubantu abanezivikeli mzimba ezibuthakathaka noma labo abalaliswe esibhedlela isikhathi eside.
Kulesi simo, ubuthi i-pyocyanin idlala indima ebalulekile: le molekyuli kulimaza amaseli esimiso somzimba sokuzivikelaKushintsha impendulo yokuvuvukala futhi kuvumela ukutheleleka ukuthi kuqhubeke futhi kube kubi kakhulu. Ngakho-ke, ukuqeda lobu buthi kuyindlela engaqondile yokunciphisa amandla amagciwane ngaphandle kokuwahlasela ngqo, into eyenziwa ukwelashwa kwama-antibiotic endabuko futhi, ekugcineni, ekhuthaza ukukhethwa kwezinhlobo ezimelana kakhulu.
Umcwaningi ovela ku-IQAC-CSIC ULluïsa Vilaplana Khumbula ukuthi ukuzivumelanisa nezimo okukhulu kwalezi zimbungulu ezinkulu kwenza kube nesidingo "sokukhuthaza amasu amasha okwelapha" avumela nciphisa izinhlobo eziningi ezimelana kanye nokunciphisa ukuqhubekela phambili kokutheleleka. Lokhu kubaluleke kakhulu kubonakala kakhulu emayunithi okunakekelwa okujulile nakwezinye izinsizakalo zezibhedlela lapho iziguli ezisengozini zigxile khona.
Umsebenzi, oshicilelwe kujenali I-ACS Pharmacology kanye neSayensi Yokuhumusha, kuhambisana kahle nalolu shintsho lwendlela yokucabanga: indlela yokwenza ukulwa negciwane Inhloso akukhona ukuqeda amagciwane, kodwa ukuvimbela izikhali zawo eziyinhloko zokuhlasela. Lokhu kunciphisa ingcindezi ekhethiwe ehlotshaniswa nokusetshenziswa kakhulu kwama-antibiotic, okungenye yezinto ezibangela inkinga yokumelana nama-antibiotic emhlabeni jikelele.
Indlela i-antibody ye-monoclonal mAb122 esebenza ngayo
Iqembu le-Nanobiotechnology for Diagnosis le-IQAC-CSIC likhiqize amamodeli egundane okuhlola i-antibody ethile ye-monoclonal, ebizwa ngokuthi mAb122I-antibody ye-monoclonal iyi-antibody iphrotheni ekhiqizwa elabhorethri eqaphela ngokunemba okukhulu i-molecule eyodwa eqondiwe; kulokhu, i-pyocyanin. Lokhu kunemba kuvumela ukuvimba okukhethiwe kakhulu komphumela wayo onobuthi.
Uma selitholakele, i-antibody yahlolwa ku- amasiko e-macrophageI-mAb122, uhlobo oluyinhloko lweseli lomzimba, yavezwa amazinga ahlukene obuthi bebhaktheriya. Imiphumela ikhombisa ukuthi i-mAb122 kunciphisa ukulimala kweseli okubangelwa yi-pyocyanin futhi kuthuthukisa kakhulu ukusinda kwala maseli okuzivikela.
Ngaphezu kwalokho, lapho i-antibody inikezwa ngaphandle kobuthi, akukho miphumela enobuthi ebonwe Le miphumela ibangelwa yi-mAb122 ngokwayo, okuwumphumela ofanele wezivivinyo zangaphambi kokwelashwa kanye nezemitholampilo zesikhathi esizayo. Lokhu kuntuleka kobuthi kungenye yezimfuneko ezibalulekile ngaphambi kokuqhubeka nezifundo kumamodeli aphelele ezilwane, futhi kamuva, nakubantu.
Umcwaningi UPilar MarcoInhloko yethimba elihole lolu cwaningo igcizelela ukuthi umqondo awukona ukubulala amagciwane, kodwa vala izindlela zayo zokusebenzisa igciwaneNgokuyisusa izikhali ngale ndlela, isiguli siyavikelwa futhi, ngesikhathi esifanayo, ingcindezi enamandla yokuziphendukela kwemvelo ebangelwa ama-antibiotic e-broad-spectrum, lapho izinhlobo ezimelana kakhulu zisinda khona, iyagwenywa.
Izinzuzo zokulwa negciwane kunemithi elwa namagciwane yakudala
Izindlela zokwelapha zokulwa namagciwane, njengalezo eziphakanyisiwe nge i-antibody ye-mAb122Zihlukile ekwelashweni okuvamile ngoba Azihlaseli ukuphila kwamagciwaneKunalokho, bahlose izici ezithile zokuba yingozi, kulokhu ubuthi be-pyocyanin. Ngokungazami ukuqeda i-microorganism, isisusa sebhayoloji sokuba amabhaktheriya akhe izinguquko eziwavikela emuthini siyancishiswa.
Lolu hlobo lwendlela lunezindlela eziningana izinzuzo ezingaba khona zezokwelaphaNgakolunye uhlangothi, kungavumela ukuthi ama-antibiotic asetshenziswe kuphela uma kudingeka ngempela, noma uma imithamo ephansiLokhu kunciphisa izingozi ezihlobene nokwelashwa okude nokujulile. Ngaphezu kwalokho, kunciphisa amathuba okukhiqiza okusha. izinhlobo ezimelana nemithi eminingi, enye yezinto ezikhathaza kakhulu impilo yomphakathi eYurophu.
Empeleni, ukwelashwa okusekelwe ku-mAb122 kungabhekwa njengokwelashwa okusebenzayo. ithuluzi elihambisanayo kunokuba kube yinto ethatha indawo ephelele yama-antibiotic. Umgomo kungaba ukuvikela amangqamuzana omzimba nokulawula ubungozi bokutheleleka, okunikeza isimiso somzimba sokuzivikela sesiguli—futhi, uma kudingeka, eminye imithi—isikhathi sokuphatha isithombe sezokwelapha.
Abalobi balolu cwaningo bagcizelela ukuthi lolu hlobo lokwelapha lungaba usizo kakhulu iziguli ezilaliswe esibhedlela ngengozi ephezulu yokutheleleka yi- Pseudomonas aeruginosa, njengabantu abanezifo zokuphefumula ezingamahlalakhona, iziguli ezinomdlavuza, noma abantu abenza izinqubo zokuhlinzwa eziyinkimbinkimbi.
Imiphumela empendulweni yokuvuvukala kanye nezinyathelo ezilandelayo
Ngaphezu kokuhlaziya umonakalo oqondile kumaseli omzimba, ithimba le-IQAC-CSIC lihlole ukuthi i-antibody iwathinta kanjani. i-mAb122 ekuphenduleni kokuvuvukalaI-Pyocyanin ishintsha ukukhiqizwa kwama-cytokine ahlukahlukene, ama-molecule alawula ukuxhumana phakathi kwamaseli esimiso somzimba sokuzivikela kanye nokuqina kokuvuvukala.
Ukuhlolwa kubonise ukuthi i-antibody kulungiswe amanye ala mazinga ngama-cytokine, okuphakamisa ukuthi ukuvimba ubuthi kungaba nomthelela omkhulu endleleni umzimba ophatha ngayo ukuvuvukala ngesikhathi sokutheleleka. Kodwa-ke, abacwaningi bagcizelela ukuthi kudingeka izifundo ezengeziwe ukuze kuqondwe ngokugcwele lokhu kushintshashintsha nokunquma ukuthi kungenzeka yini ukulungisa le mpendulo yokuvuvukala ngendlela ezuzisayo.
Okwamanje, imiphumela etholakele isesigabeni esithile kwesibelethoOkusho ukuthi, ekukhuleni kwamaseli kanye namamodeli elabhorethri okuhlola. Isinyathelo esilandelayo kuzoba ukudlulisela leli cebo ezifundweni in vivo kumamodeli ezilwane, kubalulekile ukuhlola kokubili ukuphepha nokusebenza kahle kwe-antibody ezintweni eziphilayo ngaphambi kokucabangela izivivinyo zabantu.
Uma idatha iqinisekiswa, indlela ye-mAb122 ingasungulwa njenge- indlela yokwelapha ehambisanayo lapho kubhekene nokutheleleka okubangelwa amagciwane amelana nemithi eminingi, into ebaluleke kakhulu ezinhlelweni zezempilo zaseYurophu, ebezixwayisa iminyaka eminingi ngokwanda kwamacala amagciwane amelana nemithi endaweni yesibhedlela.
Ngale ntuthuko, iqembu le-Nanobiotechnology for Diagnostics e-IQAC-CSIC lifaka isandla kwenye ingxenye yephazili ekulweni nama-superbugs: a i-antibody ye-monoclonal eyenzelwe eSpain okuyinto, ngokuvala ubuthi be-pyocyanin Pseudomonas aeruginosaIhlose ukuqinisa ukuzivikela kwesiguli, ukuvumela ukusetshenziswa okunengqondo kwama-antibiotic, nokuvula ithuba lokwelashwa okuqondile nokuphephile ngokumelene nezifo ezibangela ikhanda elibi ezibhedlela njengamanje.